226. Interstitial cystitis with Hunners ulcer Clinical trials / Disease details
Clinical trials : 145 / Drugs : 156 - (DrugBank : 51) / Drug target genes : 64 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02591199 (ClinicalTrials.gov) | September 2015 | 28/10/2015 | Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared With the Individual Components Lidocaine and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis;Bladder Pain Syndrome | Drug: URG101;Drug: Placebo;Drug: Lidocaine;Drug: Heparin | Urigen | NULL | Terminated | 18 Years | N/A | All | 92 | Phase 2 | United States |
| 2 | NCT00517868 (ClinicalTrials.gov) | August 2007 | 15/8/2007 | Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis | URG101 Pharmacodynamic and Safety Study: A Randomized, Double-blind, Placebo-controlled, Multi-center Cross-over Study to Investigate the Pharmacodynamic Profile of URG101 in Subjects With Pelvic Pain of Bladder Origin. | Painful Bladder Syndrome;Interstitial Cystitis | Drug: URG101;Drug: Placebo | Urigen | NULL | Completed | 18 Years | N/A | All | 28 | Phase 2 | United States |